cp wire

CP Wire Articles

Indivior PLC (LON: INDV) (“Indivior” or the “Company”) announced on 2/2/19 that it has entered into a definitive agreement to divest its rights related to the Sai Bo Song (buprenorphine, naloxone... read more

Wed, 02/6/19 - 09:30 am

Harpoon Therapeutics announced that it will raise up to $93 million in its IPO. The company is offering 5,400,000 shares and is granting underwriters the option to purchase up to an additional 810... read more

Mon, 02/4/19 - 09:16 pm

Avedro, Inc. (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or... read more

Mon, 02/4/19 - 10:14 am

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer, today announced that it has... read more

Sat, 02/2/19 - 03:05 pm

Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) announcedon 2/1/19 the expiration of the waiting period under the Hart-Scott-Rodino Antitrust... read more

Fri, 02/1/19 - 09:43 am

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced on 1/31/19 that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the... read more

Fri, 02/1/19 - 09:25 am
  • The FDA is requiring additional information and analyses
  • No new cliincal studies are required

Sunovion Pharmaceuticals Inc. (Sunovion) announced on 1/31/19 that the... read more

Thu, 01/31/19 - 10:19 am

BioXyTran has filed for an offering of common stock that will bring in approximately $10 million. The company has two candidates that it intends to advance to pre-clinical development with the... read more

Thu, 01/31/19 - 10:05 am

Azitra, Inc., a company developing microbiome-based cosmetics and therapeutics to treat skin diseases and conditions, announced today that enrollment has been completed for the first human safety... read more

Wed, 01/30/19 - 10:18 am

Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) reported on 1/30/19 that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer ("... read more

Wed, 01/30/19 - 10:00 am

Alector has filed for an IPO that will bring in approximately $180 million if options are exercised. The company is is focused on developing novel therapeutics that harness the brains immune... read more

Tue, 01/29/19 - 03:28 pm

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced on 1/28/19 that it is commencing a public offering of 8,000,000 Class A common shares. In addition, Kiniksa... read more

Tue, 01/29/19 - 01:24 pm

LXC Fund, based in Pittsburgh is seeking to raise $250 million according to this recent SEC... read more

Tue, 01/29/19 - 10:02 am
  • The agreement will lower out-of-pocket costs for patients
  • It will cover Brilinta prescriptions
  • Clinical outcomes will determine the level of shared costs between AstraZeneca... read more
Mon, 01/28/19 - 12:06 pm

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced on 1/26/19 that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United... read more

Mon, 01/28/19 - 10:10 am


This was a short work week for many due to MLK Day on Monday, but Tuesday started off Q4 earnings... read more
Sun, 01/27/19 - 07:07 pm
  • Coherus’ license period in the U.S. commences on December 15, 2023
  • Coherus will pay royalties to AbbVie
  • The company has six candidates in development

Coherus... read more

Fri, 01/25/19 - 10:41 am
  • ArQule is eligible to receive up to $326 million in regulatory and commercial milestone payments related to the BAL087 license agreement
  • BAL087 has U.S. and EU orphan drug... read more
Thu, 01/24/19 - 10:38 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.